Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of tivozanib versus sorafenib in refractory advanced renal cell carcinoma
2015-003607-30Phase 3Completed
- Sponsor
- AVEO Oncology
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tivozanib in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by AVEO Oncology. Primary endpoint: Progression-free survival by independent radiologic review. Started Dec 2015; status: completed.
02
Drugs
tivozanib
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2015-003607-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003607-30.